Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Growth Hormone Deficiency (Jan 2020)

Posted by Matt Breese on Jan 3, 2020

Find me on:

According to our recent payer coverage analysis for growth hormone deficiency treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for growth hormone deficiency treatments shows that under the pharmacy benefit, more than 63% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Growth Hormone_4Q2019Data snapshot as of Q4 2019

Trends: As more growth hormone products become available, payers have even more tactics available to them to manage this specialty class. In particular, payers can manage their unit costs for these therapies by contracting with manufacturers to prefer products.  

To read the full Reality Check on Growth Hormone Deficiency treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing